SC
NBIX icon

Savant Capital’s Neurocrine Biosciences NBIX Stock Holding History

Savant Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$804K Buy
5,342
+2,520
+89% +$374K ﹤0.01% 979
2026
Q1 		$372K Buy
2,822
+251
+10% +$33.3K ﹤0.01% 1065
2025
Q4 		$365K Buy
2,571
+74
+3% +$10.7K ﹤0.01% 965
2025
Q3 		$351K Buy
2,497
+87
+4% +$11.8K ﹤0.01% 945
2025
Q2 		$303K Buy
+2,410
New +$276K ﹤0.01% 948
2025
Q1 		– Sell
-16,543
Closed -$2.26M – 1298
2024
Q4 		$2.26M Buy
+16,543
New +$2.05M 0.02% 409
2024
Q3 		– Sell
-7,163
Closed -$986K – 1441
2024
Q2 		$986K Sell
7,163
-8,430
-54% -$1.16M 0.01% 594
2024
Q1 		$2.15M Buy
+15,593
New +$2.13M 0.02% 335

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Savant Capital's NBIX Position: Q2 2026 in Review

Savant Capital increased its Neurocrine Biosciences (NBIX) stake by 89% in Q2 2026, buying an estimated $374K and bringing the position to 5,342 shares worth $804K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

Savant Capital first reported a position in NBIX in Q1 2024 and has held it in 8 quarters since. The position peaked at $2.26M in Q4 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Savant Capital held 5,342 shares of Neurocrine Biosciences worth $804K as of Q2 2026.
  • Savant Capital bought 2,520 Neurocrine Biosciences shares in Q2 2026, an estimated $374K.
  • Neurocrine Biosciences made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #979 holding.
  • Savant Capital first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 8 quarters since.
  • Savant Capital's Neurocrine Biosciences position peaked at $2.26M in Q4 2024.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.